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Abstract 
The rhomboid family comprises evolutionary conserved intramembrane proteases involved in a 
wide spectrum of biologically relevant activities. A mitochondrion-localized rhomboid, called 
PARL in mammals, and conserved in yeast and Drosophila as RBD1/PCP1 and rho-7, 
respectively, plays an indispensable role in cell homeostasis as illustrated by the severe 
phenotypes caused by its genetic ablation in the various investigated species. Although several 
substrates of PARL have been proposed to explain these phenotypes, there remains a lot of 
controversy in this important area of research. We review here the putative functions and 
substrates of PARL and its orthologues in different species, highlighting areas of uncertainty, and 
discuss its potential involvement in some prevalent diseases such as type II diabetes and 
Parkinson’s disease.  
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1. Introduction 
 
The Presenilin associated rhomboid like (PARL) protease plays a pivotal but not entirely clarified 
role in the quality control and steady state maintenance of mitochondria.  PARL was originally 
identified in an interaction screen aimed at elucidating the role of Presenilin 2 in apoptosis [1], 
which explains its name. Afterwards however it became clear that PARL was a mitochondrial 
resident protein [2], and that the link to presenilin was an artifact. Although it would have been 
more correct to redefine the protein name as “mitochondrial rhomboid,” the name PARL was 
maintained for historical reasons. We suggest here that the meaning of the acronym PARL  should 
be changed to “PGAM5/PINK1 associated rhomboid like”, maintaining the historical gene name 
PARL to avoid confusion but providing a more correct association to its two identified substrates 
instead of linking it incorrectly to another intramembrane cleaving protease, presenilin. PARL is a 
member of the rhomboid family of intramembrane serine proteases and is composed of a core of 
six transmembrane helices with an additional transmembrane helix appended at the N-terminus 
[3]. Conserved serine, histidine and asparagine catalytic residues, that are contributed by different 
transmembrane helices, provide the basis for the intramembrane proteolytic activity of PARL [4]. 
In addition to the catalytic domain, PARL holds an N-terminal vertebrate-specific Pβ domain. 
Although the physiological function of the Pβ domain is unknown, its biological relevance is 
emphasized by strong sequence conservation in mammals [3].  In the current review we focus on 
the biology of PARL, its different putative substrates and the question to what extent PARL is 
involved in type II diabetes and Parkinson Disease (PD). We start with discussing the loss of 
function phenotypes described in different organisms as those provide a first insight in the 
biological relevance of this unique protease. 
 
2. Phenotypes caused by genetic manipulations of the mitochondrial rhomboid in different 
organisms  
2.1 The yeast mitochondrial rhomboid: Rbd1p/Pcp1p 
Rbd1p for rhomboid-1 or Pcp1p for “processing of cytochrome c peroxidase protein 1” is one of 
the two rhomboids in yeast. The second name derives from its first identified substrate, 
cytochrome c peroxidase, a ROS detoxifying enzyme [5]. For clarity and respecting historical 
nomenclature, we call this yeast rhomboid here Rbd1/Pcp1p and the encoding gene RBD1/PCP1.  
While following studies [6,7] convincingly demonstrated that cytochrome c peroxidase 1 is a 
genuine substrate of Pcp1p, it became also clear that lack of cytochrome c peroxidase 1 had little 
visible consequences in yeast cells.  Rbd1/Pcp1p deficient yeast strains are  unable to grow in 
glycerol medium [2] and display striking mitochondrial morphological abnormalities, such as 
mitochondrial fragmentation and aggregation, as well as loss of mitochondrial DNA nucleoids 
[2]. These observations suggested an unprecedented fundamental role of this rhomboid in 
mitochondrial biology. 
4 
 
An important clue came from the observation that the mitochondrial phenotype closely resembled 
that seen in Mgm1p deficient strains. Mgm1p, the yeast homolog of mammalian OPA1,   is a 
dynamin-like GTPase involved in mitochondrial inner membrane fusion and mitochondrial DNA 
maintenance. Yeasts lacking Rbd1/Pcp1p are defective in Mgm1p processing, leading to 
increased levels of the full-length protein and reduced levels of its lower molecular weight form 
lacking the transmembrane domain, which anchors the protein to the inner mitochondrial 
membrane [2,8]. Expression of short Mgm1p could partially complement the Δrbd1 metabolic 
phenotype, and expression of Rbd1/Pcp1p, but also of the human homolog PARL, restored the 
impaired processing of Mgm1p in the cells, while no rescue was seen with catalytically inactive 
mutants of Rbd1/Pcp1p or human PARL. This demonstrated that the cellular phenotypes and the 
absence of processing of Mgm1p were indeed caused by defective proteolytic function of the 
rhomboid, and not by some additional unknown function of this protease. 
  
2.2 The fly mitochondrial rhomboid: Rhomboid-7  
 Rhomboid-7 (rho-7) deficient flies die mostly before pupation [9]. The few individuals 
that make it to adults suffer from neurological defects and male sterility, and do not survive 
longer than three days. Testis and skeletal muscle mitochondria from rhomboid-7 flies display 
morphological alterations suggestive of defective mitochondrial fusion. The flies also have 
disturbed abnormal electroretinograms (ERG) and displayed photoreceptor degeneration after 
prolonged light stimulation. 
 Similarly to rhomboid 1 in yeast, its orthologue Rhomboid-7 in Drosophila plays a 
critical role in mitochondrial membrane morphology regulation [9]. Down regulation of 
rhomboid-7 using double-stranded RNA in Drosophila S2 cells leads to severe fragmentation of 
the mitochondrial network, and again, similar phenotypes are seen when opa1-like, the 
Drosophila orthologue of yeast MGM1, is down regulated [9]. Intriguingly, overexpression of 
Rhomboid-7 led also to increased lethality and neurological deficits in Drosophila [10]  and to a 
similar pathological mitochondrial aggregation as that seen by overexpressing PARL [9], but not 
catalytically inactive PARL. Thus, both overexpression and down regulation of Rhomboid-7 
cause neurological phenotypes in vivo and morphological alterations in mitochondria implying 
that the proteolytic activity of this rhomboid has to be kept in check.  
Interestingly, in the Rhomboid-7 overexpressing fly [10], the shorter isoform of Opa1-like was 
similarly expressed as in the wild-type, but absent  in Rhomboid-7 deficient flies, while the 
amount of full length Opa1-like was paradoxically increased. Surprisingly, the Rhomboid-7 
overexpression phenotype could then be rescued by introducing a heterozygous mutation of 
opa1-like [10], suggesting that Rhomboid-7 and Opa1-like function in a common molecular 
pathway affecting mitochondrial integrity.  
Overall, some but not all data are suggesting that Opa1-like is processed by Rhomboid 7, an 
hypothesis which could also explain the repetitively confirmed genetic interactions between 
rhomboid7/opa1-like in Drosophila,  RBD1/MGM1 in yeast, and Parl/Opa1 in mouse  [2,9–11]. 
However, the processing of Opa1-like or OPA1 by Rhomboid-7 or PARL, respectively, has not 
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been demonstrated directly by adding purified protease and substrate together. There is also lack 
of consistency in the different other experiments analyzing processing of  Opa1-like and OPA1 in 
different assays and the evidence that OPA1 is mostly processed by other mitochondrial 
proteases, makes it a  controversial issue whether OPA1 is an authentic substrate of PARL or not, 
as we will see below in our further discussion.  
A medical important link between Rhomboid-7 and a pathway involved in the pathogenesis of 
Parkinson’s Disease was made in Drosophila first. Mutations in human PINK1 and PARKIN 
genes are known to cause autosomal recessive Parkinson’s disease. Genetic interactions and 
biochemical assays have also shown that pink1 and parkin act in the same pathway controlling 
mitophagy in Drosophila [12,13]. Interestingly, Pink1 overexpression enhances, and Pink1 
inactivation decreases neurodegeneration in the eye (“rough eyes”) caused by Rhomboid-7 
overexpression [14]. The Pink1 overexpression phenotype is also characterized by “rough eyes” 
and it is partially rescued by ablation of parkin, but not by rhomboid-7. This places rhomboid-7 
upstream of pink1. Pink1 is in its turn upstream of parkin as shown previously [14],  defining as 
such an important mitophagy pathway, which is believed to contribute to (inherited) forms of 
Parkinson’s disease. Furthermore, crossing a 9myc-tagged pink1 transgenic line with the 
rhomboid-7 deficient flies, showed decreased processing of Pink1 thereby providing the first 
evidence that Pink1 is a substrate of the mitochondrial rhomboid [14]. Intriguingly, in the same 
study also a link with the mitochondrial serine protease HtrA2/Omi was made. As we will discuss 
below, full-length HtrA2 is inserted in the inner mitochondrial membrane but it becomes 
processed towards a soluble product. This soluble product was decreased in rhomboid-7 flies 
suggesting that HtrA2, like Pink1, is a substrate of this rhomboid [14]. Intriguingly, in this paper 
no effect on Opa1-like processing was observed, indicating that Rhomboid-7 was dispensable for 
processing of this substrate, despite the reported genetic interaction in other phenotypes [9,10]].  
Altogether, the data in Drosophila indicate that Rhomboid-7 is an important mitochondrial 
enzyme implicated in Pink1, and possibly HtrA2 cleavage and biology. Processing of Opa1-like 
remains controversial. Follow-up is needed to have a more definitive answer to the question 
under which experimental conditions processing of these substrates occurs, whether there are 
other substrates still to be identified, and how processing of these substrates contributes to the 
severe phenotype in the fly. Also an assay to proof that Rhomboid-7 directly cleaves the 
proposed substrates is needed.    
 
2.3 Parl in zebrafish 
Two PARL orthologues have been identified in the zebrafish: parla and parlb [15].  Both parl 
transcripts are expressed during embryonic development and in adult tissues. Morpholino-
mediated knockdown of parla and parlb simultaneously causes embryonic lethality, increased 
acridine orange staining, and altered expression of tyrosin hydroxylase mRNA and dopamine 
transporter [15], which were used as markers of dopaminergic neurons. Interestingly, 
overexpression of zebrafish pink1, but not kinase dead  pink1 or pink1 containing Parkinson’ s 
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disease causing mutations, rescues larval lethality or dopaminergic neurons abnormalities, 
indicating that parl is genetically upstream of pink1, confirming this pathway in vertebrates. 
 
2.4 Mammalian PARL  
Parl
-/-
 mice develop normally during embryogenesis but start to suffer from a progressive 
multisystem disease a few weeks after birth. This wasting disease starts within a narrow time 
window  in adulthood and is characterized by progressive muscle and immune organ atrophy, 
with  death ultimately occurring before the age of three months [11]. Massive apoptosis was 
observed in thymus and spleen from 8 weeks-old animals, and double positive CD4+/CD8+ 
thymocytes were drastically reduced. Interestingly, major mitochondrial dysfunction and 
morphological abnormalities were not found in primary cell cultures derived from these mice. 
These observations contrast remarkably with the situation in yeast and Drosophila and might 
suggest that in mammalian cells mechanism are in place that at least partially compensate for the 
role of PARL in the control of mitochondrial membrane dynamics. Further study of the 
mitochondria of fibroblasts and liver from the Parl knock out animals during the induction of 
apoptosis showed more subtle phenotypes related to apoptosis susceptibility suggesting that Parl 
exerts anti-apoptotic activity. Isolated mitochondria from liver show faster remodeling of the 
cristae and release of cytochrome c upon stimulation of apoptosis, suggesting a role of Parl in the 
morphological maintenance of cristae during the execution of induced intrinsic apoptosis. 
Remarkably, this phenotype could be rescued by a soluble form of OPA1 but not by membrane 
bound OPA1, indicating the conservation of the Parl/Opa1 interaction from yeast to mice. Again, 
no direct evidence that PARL cleaves OPA1 could be provided, largely because a cell free 
system to measure PARL proteolytic activity has not been established yet.  
It remains puzzling why in Drosophila and yeast dramatic morphological phenotypes in 
mitochondria are seen when the respective PARL homologues are inactivated, while in the Parl 
knock out MEFs and myotubes the mitochondrial network did not look altered and mitochondrial 
fusion rates were unchanged [11]. An important open question is whether the mitochondrial 
ultrastructure might be affected in cells and tissues from the Parl
-/-
 mouse at steady states.  It 
remains also to be further explored to what extent the increased apoptosis rate in these animals 
can fully explain the progressive wasting phenotype.   
 
3. PARL substrates 
The further understanding of the molecular functions of PARL depends crucially on the 
unequivocal identification of its substrates. It is also important to take into account that different 
substrates might be cleaved in different physiological conditions and in different cells or tissues, 
something which might explain some of the controversy in the field.  As we indicated already 
several candidate substrates have been identified, but the evidence remains largely indirect, and 
large knowledge gaps in the physiological and molecular function of PARL have become 
apparent. 
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3.1 OPA1 
 OPA1 is considered a substrate of mammalian PARL by analogy with the yeast system 
[2]. Further work has shown that overexpression of a soluble OPA1 fragment, but not the full 
length (membrane bound) OPA1 rescues the susceptibility to induced apoptosis of the Parl 
knockout fibroblasts [11]. Indeed cell death is normalized and the faster release of cytochrome c 
seen in Parl deficient fibroblasts is counteracted by soluble OPA1. As discussed above, such 
genetic interaction was also seen in Drosophila and yeast, indicating a conserved pathway and 
linking OPA1 and PARL functionally to each other. Further evidence for such interaction comes 
from initial biochemical studies showing that OPA1 and PARL interact in yeast two hybrid 
screenings and can be  co-immunoprecipitated from cells  [11].  
 However, several other studies have indicated that PARL is dispensable for OPA1 
processing [16]. Additional proteases are involved in the maturation of  the different  OPA1 
forms, such as isoenzymes of the ATP-dependent matrix AAA proteases paraplegin [16], 
AFG3L1 and 2 [16–18], the inner mitochondrial protease OMA1 [18], and YME1L1 [19,20]. 
Therefore, while the genetic interaction between PARL and OPA1 seems to be established, the 
question remains open whether OPA1 is indeed a substrate of PARL. Possibly PARL cleaves 
OPA1 only under specific physiological or pathophysiological conditions. Another possibility 
remains that OPA1 and PARL interact in a non-enzymatic way.  
 
 
3.2 HTRA2/OMI 
The HtrA family comprises a group of serine proteases that are characterized by the presence of a 
trypsin-like proteolytic domain and at least one PDZ domain [21]. HtrA2, high temperature 
requirement A2, is the only known HtrA family member expressed in mammalian mitochondria. 
The full length protein is expressed at the level of the inner mitochondrial membrane where it is 
subject to proteolytic maturation. Its soluble form is released into the intermembrane space, 
where it exerts an important role in mitochondrial homeostasis and protects from 
neurodegeneration [22]. In the course of apoptosis, when outer mitochondrial membrane becomes 
permeable, Htra2 is released from the mitochondrial intermembrane space to the cytosol, where, 
in contrast, it exerts pro-apoptotic effects by cleaving IAPs, inhibitors of apoptosis proteins [23–
25]. Mnd2 mice, which carry a spontaneously occurring missense mutation in Htra2/Omi 
impairing the protease catalytic activity, are affected by a lethal multisystemic phenotype 
characterized by severe subcortical neurodegeneration. The mice display increased apoptosis 
particularly affecting striatal neurons, muscle wasting, and immune organ atrophy leading to 
death before the age of 6 weeks [22,26], all of which are similarly detected in HtrA2
-/-
 mice 
carrying a targeted deletion in HtrA2 [27]. Interestingly, a similar phenotype was recapitulated by 
a neuronal specific deletion of HtrA2 [28]. Increased susceptibility to pro-apoptotic stimuli was 
reported in cultured cells carrying HtrA2 deletions or mutations [27,29,30], as well as reduced 
calcium retaining capacity [29], defective mitochondrial respiration, increased reactive oxygen 
species production [30,31], higher amount of mitochondrial proteins insoluble in mild detergents 
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[30], and increased OPA1 processing [28], suggesting that HTRA2 is a critical protease for the 
maintenance of mitochondrial quality control, but providing relative little further insight in the 
biochemical mechanism. 
The mouse wasting and immunological lethal  phenotype, as well as the increased susceptibility 
to cell death inducers show similarities with those reported  in Parl
-/-
 mice, but the first evidence 
that Htra2 could be a substrate of  Rhomboid 7 came from work in Drosophila as discussed 
above [14].  
Again, the identification of HTRA2 as a PARL substrate in mammals is more controversial. 
Starting from the above described partial phenotypical similarities between Hax1
-/-
, Htra2
-/-
, and 
Parl
-/-
 mice, the question was asked whether the three encoded proteins interact biochemically 
and functionally. Mouse fibroblasts, lymphocytes and neurons were used as model and it was 
investigated how the three proteins influence each other’s activities in apoptosis [32]. Hax1 is a 
Bcl-related protein with an anti-apoptotic activity, and, like Parl, was localized in this study to 
mitochondrial membranes. Hax1 was found to bind directly HtrA2 in different assays [32], and 
this was proposed to be needed to process HtrA2 into its intermembrane space soluble form. 
Levels of processed HtrA2 were decreased in Parl deficient fibroblasts. The authors found that 
Parl binds to Hax1 but not to HtrA2, and therefore propose that Htra2 interacts with Parl via 
Hax1. They also suggest that this would explain the similarities in phenotypes in these different 
knock out mice. However the evidence in the paper remains circumstantial.  Most importantly, a 
consecutive study raised indeed questions with regard to the proposed physical interactions 
between Hax1 and Parl, since Hax1 was found to be artefactually located in mitochondrial crude 
fractions composed by heavy membrane, but absent in purified isolated mitochondria, indicating 
that Hax1 is not a mitochondrial protein [33].  An in vivo study, investigating the role or Parl and 
Htra2 in mouse striatal neuronal injury after transient global brain ischemia, found a parallel 
decrease in neuronal Parl expression and processed Htra2 levels, again supporting, although not 
proving, the possibility that Htra2 could be a pathophysiological relevant Parl substrate in these 
stress conditions [34].  Parl down regulation through siRNA significantly worsened the outcome 
of the transient ischemia [34]. Therefore, the question whether PARL interacts with HTRA2 
independently from HAX1 remains open. 
 
3.3 PINK1 
 PINK1 is a mitochondrial kinase with a key role in regulating mitophagy, which is 
expressed in low amounts at the inner membrane of healthy mitochondria. When the 
electrochemical mitochondrial potential becomes disrupted, PINK1 is no longer imported and it 
accumulates inserted at the outer membrane of the mitochondrion, phosphorylating PARKIN in 
the ubiquitin-like domain at position Ser65 [35–38], as well as UBIQUITIN itself  also at Ser65, 
which triggers mitochondrial PARKIN recruitment [38–43]. This sets off a pathway involving 
recruitment of the E3 ubiquitin ligase PARKIN, ubiquitination of outer mitochondrial membrane 
proteins, and selective autophagic engulfment of the defective organelles [44–46]. This process is 
thought to dispose of dysfunctional mitochondria, assuring autophagy-mediated mitochondrial 
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quality control. According to several authors, defective mitophagy is a major process in the 
pathogenesis of PINK1-related Parkinson’s disease. In addition, PARKIN and PINK1 seem to be 
involved in another form of mitochondrial quality control mechanism, independent from 
macroautophagy, through disposal of small vesicular structures containing oxidized proteins and 
lipids, called mitochondrial derived vesicles [47,48] 
 The first evidence that PINK1 was a mitochondrial rhomboid substrate came from the 
already cited work by Withworth et al. [14] showing that  rhomboid-7 deficient flies have 
impaired  Pink1 processing. Soon after, several studies confirmed this in mammalian cells. Large 
mitochondrial accumulation of PINK1 is observed upon down regulation or genetic activation of 
PARL [44,49–51]. Using RNA interference, three other mitochondrial proteases were also found 
to affect levels of full length PINK1, including mitochondrial processing peptidase (MPP), the 
AFG3L2 subunit of the m-AAA protease, and ClpXP [51]. The contribution of each of these 
cleavages to the function of PINK1 needs further work but they might be involved in 
compensatory mechanisms in PARL knock out cells. In functional mitochondria with a preserved 
electrochemical potential, full length 63 kDa PINK1 is imported inside mitochondria through the 
outer membrane translocase TOM and inner membrane translocase TIM complexes. In the matrix 
the mitochondrial targeting signal is removed by MPP [51], and the remaining 60 kDa protein is 
inserted in the inner mitochondrial membrane. This protein is rapidly cleaved in the 
transmembrane domain by PARL at position Ala-103-Phe-104 to generate a 53 kDa form [50], 
which rapidly  retrotranslocates into the cytosol where it is degraded by the proteasome in 
agreement with the N-end rule by E3 ubiquitin ligases UBRs with a fast turnover [52]. This 
whole cycle explains why PINK1 steady states levels are very low in healthy cells (Figure 1A). In 
depolarized mitochondria, import of PINK1 is inhibited and the full length form accumulates at 
the outer membrane (Figure 1B) [44] where it exerts ubiquitin phosphorylation as discussed. In 
conclusion, strong genetic and biochemical evidences support PINK1 as a real PARL substrate, 
although if the function of PARL-induced PINK1 cleavage is limited to regulate its turnover is 
still not understood, and the consequences of PARL deletion on PINK1 processing in vivo are 
actually unknown. Thus, amajor question remains why under normal conditions such a 
complicated processing of PINK1 is maintained. It would be reasonable to hypothesize that this 
expensive cycle of synthesis, mitochondrial transport and degradation is not only there to control 
mitophagy, which is not readily occurring in normal cells under non stressful conditions. One is 
tempted to speculate that the different steps of this process could also serve the maintenance of a 
not yet understood purpose. It looks like PINK1 probes the different compartments of the 
mitochondrion during its journey, and we hypothesize that the successful fulfillment of this 
journey with final dispensing of the protein might signal to the cell that mitochondria are in 
check. It is clear that PARL cleavage plays a pivotal role in the transformation of the membrane 
bound, mitophagy induction competent protein, to a soluble kinase whose function remains 
unfortunately still unknown at this moment.  
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3.4 PGAM5 
 PGAM5 is a member of the phosphoglyceromutase enzymes which are involved in the 
conversion of 3-phosphoglycerate to 2-phosphoglycerate in glycolysis. PGAM5 stands apart in 
the family because it has a mitochondrial localization signal and lost its mutase activity during 
evolution. In contrast, it acquired Ser/Thr phosphatase activity [53]. PGAM5 was originally 
reported as an interactor of the oxidative stress sensor KEAP1 [54]. The first evidence of 
PGAM5 being a substrate of PARL came from Sekine et al. [55]. In contrast to the assumption 
that PGAM5 is a resident protein of the  outer mitochondrial membrane [56], the protein was 
later recovered from the  inner mitochondrial membrane. It was also found that it was 
proteolytically processed and that this increased when the mitochondrial potential collapsed, 
which is the opposite of PINK1 [55]. The authors also found that the processing of PGAM5 could 
be inhibited with dichloroisocoumarin, a serine protease inhibitor that was shown before to 
inhibit rhomboids [57]. This led them to test the effects of PARL down regulation, which resulted 
in a clear PGAM5 processing abnormality characterized by accumulation of the unprocessed 
form with a paralleldecrease of the processed protein. PARL down regulation also blocked the 
increase in PGAM5 processing after mitochondrial depolarization with mitochondria uncoupling 
drugs. Moreover overexpression of PARL, but not catalytically inactive PARL, induced a 
remarkable increase in the levels of processed PGAM5. Interestingly, after the addition of 
uncoupling agents to cultured cells, the authors noticed that the progressive increase in the 
processing of PGAM5 paralleled the increase in levels of PINK1. Then, they could show that the 
interactions between PARL and the two substrates PINK1 and PGAM5 were inversely correlated 
and that, in polarized mitochondria, PARL preferentially cleaves PINK1, while after 
mitochondrial depolarization PARL preferentially cleaves PGAM5, which suggests that PGAM5 
processing might have a role in mitochondrial stress response. In conclusion, strong biochemical 
evidence supports PGAM5 as a genuine PARL substrate. However, the precise physiological 
functions of PGAM5 are not clear and therefore the significance of this processing step remains 
unclear as well. It is very intriguing that PINK1, a kinase, and PGAM5, a phosphatase, are 
regulated in opposite ways by PARL. We speculate that they could regulate shared substrates, 
although there is no evidence supporting this idea at the moment. Phosphoproteomics 
experiments on Pink1
-/-
 and Pgam5
-/-
 could be used to evaluate this hypothesis. Another 
outstanding question is to what extent PARL processing of these substrates is physiologically 
important. One approach could involve crossings of the different available mouse strains and 
check whether Parl, Pink1, and Pgam5 interact genetically and modify the severe phenotype in 
Parl
-/-
 mice.  
 
4. Putative functions of PARL 
While the functions of the mitochondrial rhomboid has been thoroughly dissected by several 
independent studies in yeast [2,7,8,58,59], for vertebrates the studies are more scanty. As a result, 
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our understanding of PARL functions remain limited, and sometime the available data are 
contradictory or indirectly deduced from the available knowledge about their substrates. 
 
4.1. Role of PARL in apoptosis 
 The wasting phenotype of the Parl
-/-
 mouse was attributed to increased apoptosis rates 
[11]. This was ascribed to the faster cytochrome c release seen in cell cultures after treatment 
with several intrinsic pro-apoptotic stimuli, such as staurosporine, hydrogen peroxide, etoposide, 
but not with the extrinsic stimulator TNF-α. An increase in apoptotic markers was also reported 
in the striatum of mice after treatment with siRNA against Parl and transient global ischemia 
[34]. We discussed above already potential mechanisms and substrates linking PARL to 
apoptosis. Soluble OPA1 and HTRA2 are obvious candidates [11,32], although their status as 
direct PARL substrates is less clear. PGAM5 is a well-documented PARL substrate (see above 
paragraph), and it has been implicated in different modalities of cell death including apoptosis 
[53,60], and necroptosis [61], but it remains to be shown if abnormal processing of PGAM5 is 
necessary and sufficient to cause apoptosis in the mice. Importantly it is not excluded and 
actually likely that also other mechanisms contribute to the wasting phenotype in the Parl
-/-
 mice. 
The in vivo evidence for increased apoptosis in the Parl
-/-
 mouse was indeed largely limited to 
immune organs. Altogether, while the data clearly indicate a critical role for PARL in protecting 
cells from cell death in vitro and in vivo, the cause of the reduced life span and of the cachectic 
phenotype of the Parl
-/-
 mouse remains to be further investigated. 
 
4.2 Role of PARL in shaping mitochondrial morphology  
 Mitochondria constantly fuse and divide with each other, exchanging membranes, 
proteins, solutes, and mitochondrial DNA, to dynamically adapt within time and space to local 
metabolic needs, facilitate mitochondrial transport, ascertain quality control of the organelle 
through complementation or segregation of the damaged ones from the mitochondrial network. 
Heavily damaged mitochondria are eliminated through mitophagy. We discussed the effects of 
loss of function of RBD1/PCP1 and rho-7 on mitochondrial shape. Mitochondrial fusion rates 
and steady state mitochondrial network morphology was found to be normal in fibroblasts 
derived from the Parl
-/-
 mouse [11]. However, in another study changes in mitochondrial cristae 
architecture were mentioned in skeletal muscle of mice locally injected with Adenoviral 
expressed Parl-siRNA [62] and similar mitochondrial morphological defects were detected in 
PARL downregulated cultured human myotubes. 
 The situation might be quite complicated as a shorter version of PARL, called PACT 
(standing for PARL C terminus), was found to induce mitochondrial fragmentation in cell 
cultures [63]. These authors propose that PARL is subject to two consecutive processing events; a 
first one is constitutive and occurs at position AA 52-53 to remove the mitochondrial targeting 
sequence, resulting in the generation of MAMP, mature mitochondrial PARL. A second, so-
called, β-cleavage, is developmentally regulated and cell type specific [3]. It occurs in the matrix 
oriented N terminus domain of PARL at position AA 77-78, producing a 25 amino acid residue 
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long peptide which was, surprisingly, localized into the nucleus, and the remaining 33.5 kDa 
mitochondrial resident protein, PACT [3]. The β cleavage site is only conserved in mammals, 
suggesting a species specific differentiation of function during evolution. Interestingly PACT was 
only found in cells overexpressing WT PARL but not in cells expressing catalytically inactive 
PARL mutants, suggesting that β cleavage is executed by another protease activated by PARL or 
by PARL itself. A follow-up study from the same group identified three phosphorylation sites, at 
Ser-65, Thr-69, and Ser-70, with a critical role in regulating PARL β cleavage, and this cleavage  
was found to be required to induce mitochondrial fragmentation [63].  It should be pointed out 
that all these experiments were performed in vitro in overexpressing cells, and the physiological 
significance of this process needs further investigation in vivo. This work suggests however 
complicated biochemical regulations of PARL function. Altogether, while the mitochondrial 
rhomboid plays indeed a role in mitochondrial shape in yeast and Drosophila, it is not clear if this 
also happens in mammals. Thus, more work is needed to clarify the role of PARL in modulating 
mitochondrial morphology and ultrastructure in vivo in mammals, as well as endogenous PARL 
regulation. 
 
4.3 Role of PARL in mitochondrial function regulation and biogenesis 
 The characterization at the molecular and biochemical level of the functional 
consequences of Parl ablation on mitochondrial function is extremely limited. Mitochondrial 
respiration as well as the electrochemical mitochondrial potential appeared normal in cultured 
cells and muscle and liver tissues [11]. This led to the conclusion that under steady state 
conditions, Parl had no direct effect on the electron transport chain and supported the idea that the 
wasting phenotype in the mice was caused by unchecked apoptosis. This seems contradictory to 
what was found in another study, linking PARL deficiency to insulin resistance in diabetic 
patients through mitochondrial dysfunction and reduced mitochondrial mass [62]. PARL mRNA 
was reduced in muscle from patients with insulin resistance and type 2 diabetes, and PARL 
protein expression levels were reduced in primary myotubes from both type 2 diabetes patients 
and elderly individuals. Parl down regulation in skeletal muscle through intramuscular injection 
of Adenoviral PARL siRNA decreased mitochondrial mass through reduced Pgc1α expression 
and also lowered Opa1 levels. A similar mitochondrial dysfunction was found in primary human 
muscle cells treated with adenoviral expressed siRNA against PARL: mitochondrial mass, 
mitochondrial DNA, OPA1 levels, as well as oxygen consumption, cytochrome c oxidase activity 
and palmitate oxidation all decreased, while reactive oxygen species increased. Moreover, 
myotubes treated with the short nuclear targeting PARL β fragment responded with increasing 
expression of SIRT1 and OPA1, and elevated mitochondrial biogenesis. Conversely, myoblasts 
overexpressing PARL showed increased oxygen consumption. The authors concluded that PARL 
plays an important role in regulating mitochondrial mass levels by stimulating mitochondrial 
biogenesis through the nuclear targeting PARL β peptide, and mitochondrial function through 
full length PARL, thus preventing the development of reduced insulin sensitivity. Interestingly, 
polymorphisms in the PARL gene detected upon a genetic screen of 1086 individuals were found 
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to correlate significantly with mitochondrial DNA levels in peripheral blood cells [64]. If PARL 
was indeed implicated in modulating mitochondrial function and biogenesis, impairment of 
mitochondrial function and severely decreased mitochondrial mass would be expected in tissues 
of the Parl
-/- 
mouse. 
 In conclusion, the involvement of PARL in regulating mitochondrial function and mass 
deserves further investigation, including mitochondrial bioenergetics and mitochondrial 
ultrastructural analysis. 
 
4.4 Role of PARL in modulating mitophagy 
 Robust evidence indicate that both PINK1 and PGAM5, two proteins involved in 
mitochondrial autophagic turnover, are genuine substrates of mammalian PARL [44,49–
51,55,65,66] at least in vitro. Depolarization of mitochondria prevents processing of Pink1 by 
Parl because Pink1 gets stuck at the outer membrane. In one study, Parl KO MEFs transfected 
with PINK1-YFP, were found to have  unchanged Parkin recruitment after depolarization of 
mitochondria with CCCP [44]. Another study reported a comparable PARKIN translocation to 
mitochondria in WT and PARL KO HEK293T cells [51]. At difference with these two studies, 
Parl KO MEFs turned out to recruit less efficiently Parkin to mitochondria in an third study [65]. 
Reintroduction of WT PARL, but not catalytically inactive mutant PARL, was able to rescue this 
biochemical phenotype. A fourth scenario was described in a study employing a doxycycline-
induced construct to down regulate PARL in HEK293T cells. Here PINK1 was found to be 
retrotranslocated from the inner mitochondrial membrane to the outer mitochondrial membrane, 
leading to massive mitochondrial PARKIN recruitment and induction of mitophagy even in the 
absence of mitochondrial depolarizing agents [67].  
In conclusion, PARL is likely involved in mitophagy regulation, at least indirectly, as suggested 
by identification of PINK1 and PGAM5 as substrates, but the mechanism remains puzzling as 
illustrated by the very opposing results found in different experimental paradigms. One drawback 
is that the study of the involvement of PARL in this pathway is mostly limited to in vitro studies, 
often complicated by the use of protein overexpression and the prolonged use of very high 
concentrations of mitochondrial uncoupling drugs, which not only completely abolish the 
mitochondrial potential of the whole mitochondrial network in a very unphysiological manner, 
but also leads to a number of biochemical side effects such as enhanced ATP consumption, as a 
consequence of the ATP hydrolysis caused by reverse catalytic activity of ATP synthase. 
Moreover, the mitochondrial sublocalization of PINK1 and PGAM5 remains also controversial, 
with reports placing these substrates in both the mitochondrial outer membrane and in the inner 
membrane, as well as in the cytosol. It is possible that different pools exist for both proteins, but a 
more dynamic view as explained above is probably closer to the real situation. Finally, it will be 
important to understand the effects of the cleaved fragments versus the uncleaved PINK1 and 
PGAM5, as well as of any additional substrate that might become identified in the future. 
 
5. A possible role of PARL in diabetes and Parkinson disease 
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Type 2 diabetes is a pandemic disease, resulting in a huge health care burden because of its 
severe systemic complications at the level of the vascular system, the eye, and renal function. The 
implication of mitochondrial impairment, caused by decreased mitochondrial mass, impaired 
oxidative phosphorylation capacity, and increased reactive oxygen species production has been 
suggested by several studies. 
Gene variants in the PARL gene were first reported as a putative risk factor for type 2 diabetes in 
a gene expression study in skeletal muscle aimed to identify differentially expressed 
mitochondrial genes in the Psammomys obesus, a rodent susceptible to metabolic diseases 
including obesity and type 2 diabetes [68]. Parl gene expression was significantly reduced in the 
diabetic rodents, while this deficit improved after exercise training. A population of 1031 human 
North American subjects was screened and a polymorphism Leu262Val was found in PARL 
which was associated with increased plasma insulin concentrations, a known risk factor for 
diabetes. However, another study conducted on a sample of 3666 individuals, failed to detect this 
association, and concluded that  this genetic variant was unlikely to be an important contributor 
to insulin resistance in the UK population [69]. A third study, conducted on a sample of 613 Irish 
individuals also failed to identify the association between this PARL gene variant and plasma 
insulin, but found associations between homozygous carriers of this variant and 
microalbuminuria, a marker of diabetic nephropathy, as well as with the occurrence of earlier 
onset of type 2 diabetes [70]. Decreased PARL protein and gene expression, and lower 
mitochondrial mass were found in both skeletal muscle biopsies and cultured myotubes from 
elderly individuals and patients with type 2 diabetes compared to controls [62]. Down regulation 
of PARL in muscle, as discussed above, caused increased triglyceride content and impaired 
insulin signaling. High fat diet increased insulin resistance and decreased Parl expression in mice. 
The authors concluded that PARL expression may contribute to the mitochondrial abnormalities 
found in ageing and type 2 diabetes [62]. Altogether, while the genetic variations in the PARL 
gene are likely very rare and modest risk factors for the development of type 2 diabetes, PARL 
may be an interesting candidate to study in further depth the mitochondrial pathophysiology at 
the basis of this disease. 
 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, leading to 
severe disability and huge health care impact. The first link between PD and PARL was made 
when  Pink1 was identified as a substrate of Rhomboid-7 in Drosophila [14]. Following studies 
confirmed that PINK1 was a substrate of the mitochondrial rhomboid  in mammals [44,49–
51,65]. Interestingly, a missense mutation, c.230G>A, was found in the PARL gene in two 
patients affected by PD [65]. This mutation results in a substitution of a serine to an asparagine at 
codon 77 (p.Ser77Asn) and is placed in a highly conserved phosphorylation site in the PARL N 
terminus with a critical role in regulation of PARL β cleavage discussed above [3,63,65]. 
However, two independent studies, one in 92 patients affected by early onset PD [71], another in 
more than 2000 German patients including both sporadic and familial cases [72], failed to detect 
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the presence of c.230G>A or of other pathogenic mutations in the PARL gene, suggesting that 
PARL mutations are an extremely rare genetic cause of PD.  
Interestingly, another link between PD and PARL was indirectly provided by the description of a 
late onset Parkinsonian phenotype in the Pgam5
-/-
 mouse [66]. These mice were affected by 
dopaminergic neurodegeneration in the substantia nigra pars compacta at 1 year of age, and show 
decreased dopamine and dopamine metabolites, and locomotor impairment which improved by  
L-DOPA therapy [66]. However, other reports from independent groups reported different 
phenotypes in the Pgam5
-/- 
mouse, such as decreased body weight, reduced survival in males, and 
impaired inflammasome activation [73], and increased resistance to combined cold stress and 
fasting, as well as resistance to high-fat-diet-induced obesity [74]. 
Altogether, the available evidence indicates at least an indirect role of PARL in PD 
pathophysiology through its substrate PINK1, and potentially PGAM5, although how their 
cleavage by PARL might possibly affect the development of PD is not yet understood. Variants 
in the PARL gene seems to be very rare causes of PD, but genetic screenings of the whole PARL 
gene exons on larger samples of patients with PD from different ethnic groups are warranted.  
 
 
 
 
6. Conclusions 
 
The discovery of a mitochondria-localized rhomboid more than one decade ago opened a new 
area of investigation in mitochondrial biology and brought the field of regulated intra-membrane 
proteolysis also inside the mitochondria. The presence of severe phenotypes in all species where 
the mitochondrial rhomboid has been genetically ablated unequivocally indicates a crucial 
physiological role of this rhomboid in cell homeostasis and the absence of redundant biochemical 
pathways leading to effective compensation. Pioneering studies have defined a limited number of 
substrates and a role in regulating different critical aspects of mitochondrial biology, including 
mitochondrial morphology, apoptosis, mitophagy, mitochondrial metabolism, and in the 
pathophysiology of prevalent diseases such as diabetes and Parkinson’s disease. Although several 
of these reports, especially in mammals, are preliminary and often contradictory, and many 
observations  are limited to in vitro analysis, often further confounded by protein overexpression, 
the available evidence clearly indicates a fundamental role of PARL in mitochondrial biology. 
Additional studies are warranted to confirm the proposed PARL substrates in vivo, investigate 
the presence of additional substrates, and define their significance in physiology and in human 
diseases. Several approaches could be used to identify novel mitochondrial rhomboid substrates 
and interactors, including coimmunoprecipitation, copurification using affinity tags, cross-linking 
experiments, or mass spectrometry based degradome analysis. A careful reevaluation of the 
physiological mitochondrial functions of PARL in different animal species is also needed in order 
to define more precisely which biological functions are conserved during evolution. Finally we 
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propose to associate the P in the name PARL no longer to Presenilin, but to the known substrates 
PGAM5 and PINK1, which could help to make the literature on these intriguing proteins less 
confusing.   
 
 
Legend to figure 
Schematic cartoon illustrating PARL, the mitochondrial rhomboid located in the inner 
mitochondrial membrane (IMM), and its putative interacting proteins. (A) In polarized 
mitochondria with preserved mitochondrial membrane potential (Δψ), PARL preferentially 
cleaves PINK1. PINK1 is normally imported through the TOM/TIM complexes, its 
mitochondrial targeting signaling is cleaved by matrix MPP, it is inserted in the inner 
mitochondrial membrane through its transmembrane domain, at which level it is cleaved by 
PARL. Then, through still unknown mechanisms, it is thought to be rerouted to the cytosol, 
where it is rapidly degraded by the ubiquitin-proteasome system. Although still under debate, 
PGAM5 could potentially have a double mitochondrial sublocalization, an inner membrane pool, 
which is only marginally cleaved by PARL in polarized mitochondria, and possibly an outer 
membrane pool which may possibly interact with KEAP1 and the antioxidant response regulator 
NRF2 [56]. It is possible, but controversial, that PARL also cleaves OPA1, generating a shorter 
intermembrane space (IMS) OPA1 pool which serves keeping mitochondrial cristae junction 
tight, delaying cristae remodeling during apoptosis [11], as well as the peptidase HTRA2 [32], 
generating its mature intermembrane space resident from, which protects from 
neurodegeneration. (B) In depolarized mitochondria with collapsed mitochondrial potential (Δψ), 
PINK1 is no longer fully imported inside the mitochondrial matrix passing through TOM and 
TIM complexes and it is inserted in the mitochondrial outer membrane (OMM) (directly, or 
indirectly through rerouting to the outer membrane), through its transmembrane domain, leading 
to PARKIN recruitment from the cytosol to the mitochondria and activating mitophagy, which 
eliminates dysfunctional mitochondria. In these stress conditions, PARL cleaves PGAM5 
generating a 24 aminoacids shorter form [55] of which both function and mitochondrial 
sublocalization are not known. A putative pool of PGAM5 residing in the outer mitochondrial 
membrane membrane has been reported to dephosphorylate FUNDC1, activating mitophagy [75]. 
In particular conditions causing necroptosis induction, requiring high RIP3 expression and 
caspase 8 inhibition, and only in specific cell types, the putative outer membrane pool of PGAM5 
has been reported as a component of the necrosome complex responsible for dephosphorylation 
and activation of the mitochondrial fission protein DRP1 [61], although following studies have 
shown PGAM5 is dispensable for necroptosis execution, as discussed above. 
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